|
| Press Releases |
|
 |
|
| Friday, August 15, 2025 |
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2025 (the 'Period'), reporting growth in both revenue and net profit despite an uncertain macroeconomic landscape. more info >> |
|
| Friday, March 7, 2025 |
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its annual results for the year ended December 31, 2024 (the 'Year'), reporting record-high revenue and healthy net profit despite the challenging business landscape. more info >> |
|
| Friday, August 16, 2024 |
|
|
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024 |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2024 (the 'Reporting Period), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges. more info >> |
|
| Wednesday, April 24, 2024 |
|
|
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China |
| OrbusNeich Medical Group Holdings Limited announced today that the Group's joint venture OrbusNeich P+F Company Limited ("ON P&F") has commenced the clinical trial for the TricValve Transcatheter Bicaval Valve System ("TricValve"), to treat patients with hemodynamically relevant tricuspid insufficiency and caval reflux, on April 22, 2024 across Mainland China. more info >> |
|
| Thursday, March 7, 2024 |
|
|
OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Monday, November 27, 2023 |
|
|
OrbusNeich Acquires 84% Stake in Indonesian Distributor PT Revass for Approximately US$15 Million |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich", 6929.HK), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Thursday, November 23, 2023 |
|
|
OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Thursday, August 17, 2023 |
|
|
OrbusNeich FY2023 Interim Net Profit Triples to US$25.2 Million, Total Revenue Increases by 18.2% to US$81.4 Million |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today announced its interim results for the six months ended 30 June 2023, reporting growth in both revenue and net profit. more info >> |
|
| Monday, May 8, 2023 |
|
|
OrbusNeich Kicks Off Clinical Study of Scoreflex TRIO, Completing China's First PCI Intervention Procedure with High-Pressure, Three-wire Scoring Balloon Dilatation Catheter |
| OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
| Tuesday, March 28, 2023 |
|
|
OrbusNeich Plans to Set up Its Largest R&D and Production Base in Fuchun Bay New Town, Hangzhou, the PRC |
| OrbusNeich Medical (Zhejiang) Company Limited ("OrbusNeich Zhejiang"), a wholly-owned subsidiary of OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
BCQ (01963.HK) to Pay RMB 585 Million Cash Dividend, Driving Share Price and Yield Upside
Dec 25, 2025 17:23 HKT/SGT
|
|
|
Avantor Appoints Gladys Wang as Vice President, Bioprocessing Commercial, Asia, Middle East & Africa
Dec 24, 2025 13:20 JST
|
|
|
AEON Credit Service Net Profit Surges 28.1% to HK$352.7 Million for First Nine Months of FY2025/26
Dec 23, 2025 22:07 HKT/SGT
|
|
|
Tohoku University and Fujitsu utilize Causal AI to discover superconductivity mechanism of promising new functional material
Dec 23, 2025 14:58 JST
|
|
|
THE HANEDA GODZILLA GLOBAL PROJECT OFFICIALLY KICKS OFF COMPLETION EVENT 
Dec 23, 2025 13:00 HKT/SGT
|
|
|
Holiverse Announces Development of Offline AI Device to Return Data Control to Users
Dec 23, 2025 10:00 HKT/SGT
|
|
|
Toward an Athlete- and Planet-Friendly Hakone Ekiden: All Vehicles Provided for the 2026 Race Will Be Electrified
Dec 23, 2025 3:18 JST
|
|
|
MHI Group to Accelerate Development of Digital Talent
Dec 23, 2025 2:57 JST
|
|
|
MHI and EXEO Group Build and Begin Commercial Use of Japan's First GPU Servers with Two-Phase DLC
Dec 23, 2025 2:20 JST
|
|
|
USA EPA Approval Conditions Accepted for Graphene Coating THERMAL-XR(R)
Dec 22, 2025 20:39 HKT/SGT
|
|
|
Saat & Saat Acquires Turkish Apparel Leader Aydinli Group, Expanding U.S. Polo Assn. Markets Across Turkey, the Middle East, Eastern Europe, and North Africa
Dec 22, 2025 20:00 HKT/SGT
|
|
|
Sri Lanka and the Middle East's top real estate achievements recognised at 2025 PropertyGuru Asia Property Awards
Dec 22, 2025 09:00 HKT/SGT
|
|
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 10:30 HKT/SGT
|
|
|
Air T, Inc. Announces Closing of Regional Express Acquisition
Dec 19, 2025 06:10 HKT/SGT
|
|
|
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Dec 19, 2025 3:24 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
